Read Time:8 Second
The hemophilia A treatment could become the company’s second gene therapy to enter the U.S. market after Beqvez, which was cleared in April for hemophilia B.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
